New eczema drug shows promise in Mid-Stage trial
NCT ID NCT07011706
First seen Nov 01, 2025 · Last updated May 01, 2026 · Updated 26 times
Summary
This study tests a new drug called ATI-045 in 110 adults with moderate-to-severe atopic dermatitis (eczema). Half receive the drug, half receive a placebo, and neither the patients nor doctors know who gets which. The main goal is to see if ATI-045 reduces eczema severity and itching over 24 weeks. Participants must have had eczema for at least 6 months and not responded well to topical treatments.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ATOPIC DERMATITIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Aclaris Clinical Site
Phoenix, Arizona, 85008, United States
-
Aclaris Clinical Site
Tucson, Arizona, 85704, United States
-
Aclaris Clinical Site
Beverly Hills, California, 90212, United States
-
Aclaris Clinical Site
Encino, California, 91436, United States
-
Aclaris Clinical Site
Huntington Beach, California, 92647, United States
-
Aclaris Clinical Site
Sherman Oaks, California, 91403, United States
-
Aclaris Clinical Site
Thousand Oaks, California, 91320, United States
-
Aclaris Clinical Site
Hollywood, Florida, 33486, United States
-
Aclaris Clinical Site
Jacksonville, Florida, 32256, United States
-
Aclaris Clinical Site
Margate, Florida, 33063, United States
-
Aclaris Clinical Site
Wellington, Florida, 33449, United States
-
Aclaris Clinical Site
Atlanta, Georgia, 30315, United States
-
Aclaris Clinical Site
Savannah, Georgia, 31405, United States
-
Aclaris Clinical Site
Lafayette, Indiana, 47906, United States
-
Aclaris Clinical Site
Ann Arbor, Michigan, 48103, United States
-
Aclaris Clinical Site
Troy, Michigan, 48084, United States
-
Aclaris Clinical Site
Ridgeland, Mississippi, 39157, United States
-
Aclaris Clinical Site
Missoula, Montana, 59804, United States
-
Aclaris Clinical Site
New York, New York, 10128, United States
-
Aclaris Clinical Site
The Bronx, New York, 10455, United States
-
Aclaris Clinical Site
Cary, North Carolina, 27518, United States
-
Aclaris Clinical Site
Wilmington, North Carolina, 28405, United States
-
Aclaris Clinical Site
Philadelphia, Pennsylvania, 19103, United States
-
Aclaris Clinical Site
Myrtle Beach, South Carolina, 29588, United States
-
Aclaris Clinical Site
Dallas, Texas, 75230, United States
-
Aclaris Clinical Site
Houston, Texas, 77004, United States
-
Aclaris Clinical Site
The Woodlands, Texas, 77380, United States
-
Aclaris Clinical Site
Providence, Utah, 84332, United States
-
Aclaris Clinical Site
Seattle, Washington, 98004, United States
-
Aclaris Clinical Site
Spokane, Washington, 99202, United States
-
Aclaris Clinical Site
Barrie, Ontario, L4M 7G1, Canada
-
Aclaris Clinical Site
Toronto, Ontario, M2N 3A6, Canada
-
Aclaris Clinical Site
Montreal, Quebec, H1Y3L1, Canada
-
Aclaris Site
Markham, Ontario, L3P 1X3, Canada
-
Aclaris Site
Mississauga, Ontario, L4Y 4C5, Canada
-
Aclaris Site
Richmond Hill, Ontario, L4B 1A5, Canada
-
Aclaris Site
Toronto, Ontario, M4W 2N2, Canada
-
Aclaris Study Site
Bryant, Arkansas, 71913, United States
-
Aclaris Study Site
Encinitas, California, 92024, United States
-
Aclaris Study Site
Los Angeles, California, 90045, United States
-
Aclaris Study Site
Oceanside, California, 92056, United States
-
Aclaris Study Site
Santa Monica, California, 90404, United States
-
Aclaris Study Site
Coral Gables, Florida, 33134, United States
-
Aclaris Study Site
North Miami Beach, Florida, 33162, United States
-
Aclaris Study Site
Sweetwater, Florida, 33172, United States
-
Aclaris Study Site
Tampa, Florida, 33607, United States
-
Aclaris Study Site
Boise, Idaho, 83706, United States
-
Aclaris Study Site
Clarksville, Indiana, 47129, United States
-
Aclaris Study Site
Indianapolis, Indiana, 46250, United States
-
Aclaris Study Site
West Lafayette, Indiana, 47906, United States
-
Aclaris Study Site
Bowling Green, Kentucky, 42104, United States
-
Aclaris Study Site
Auburn Hills, Michigan, 48326, United States
-
Aclaris Study Site
Saint Joseph, Missouri, 64506, United States
-
Aclaris Study Site
New York, New York, 10023, United States
-
Aclaris Study Site
New York, New York, 10075, United States
-
Aclaris Study Site
Camp Hill, Pennsylvania, 17011, United States
-
Aclaris Study Site
San Antonio, Texas, 78213, United States
-
Aclaris Study Site
San Antonio, Texas, 78218, United States
-
Aclaris Study Site
Webster, Texas, 77598, United States
-
Aclaris Study Site
Norfolk, Virginia, 23502, United States
Conditions
Explore the condition pages connected to this study.